Cadence has raised $100 million in Series C funding to scale its AI-powered chronic care platform that monitors patients at home and adjusts medications in real time. The startup is valued at $1.23 billion and partners with health systems to treat conditions including heart failure, hypertension, and diabetes. The financing signals continued investor interest in closed-loop or decision-support models that move beyond one-off telehealth check-ins toward ongoing remote management. For health systems, the key operational variable is whether medication adjustment logic can reduce clinical workload while improving adherence and outcomes. As remote monitoring platforms compete on clinical performance and integration burden, Cadence’s scaling push underscores how payers and provider networks are evaluating AI-enabled medication workflows that can be deployed at scale.